SY-14556 / Shouyao Holdings - LARVOL DELTA

Discovery of SY-14556, a highly potent and selective small molecule reactivator of p53 Y220C mutant with differentiated preclinical profile (AACR 2026) - "Pharmacologic stabilization and reactivation of the Y220C mutant to a wild-type-like conformation is a validated therapeutic strategy, as demonstrated by the clinical activity of PC14586 (rezatapopt). In conclusion, SY-14556 is a best-in class p53-Y220C reactivator with robust preclinical efficacy and safety. These data support its advancement into clinical trials for p53 Y220C-mutant solid tumors."

Preclinical • Oncology • Solid Tumor • CDKN1A